Immunovant discontinues batoclimab after failed trials, pivots fully to IMVT-1402
Filed May 20, 2026 · Period ending March 31, 2026 · Compared to 10-K May 29, 2025 · ~1 min read
5 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade IMVT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
View original filing on SEC.gov
Generated by AI · May 26, 2026 5:41 AM